PHASE I STUDY OF ABT-199 (GDC-0199) IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA: RESPONSES OBSERVED IN DIFFUSE LARGE B-CELL (DLBCL) AND FOLLICULAR LYMPHOMA (FL) AT HIGHER COHORT DOSES

被引：0
|
作者：
Davids, M. S. [1 ]
Seymour, J. F. [2 ]
Gerecitano, J. F. [3 ]
Kahl, B. S. [4 ]
Pagel, J. M. [5 ]
Wierda, W. G. [6 ]
Anderson, M. A. [7 ,8 ]
Rudersdorf, N. K. [9 ]
Gressick, L. A. [9 ]
Montalvo, N. P. [9 ]
Yang, J. [9 ]
Zhu, M. [9 ]
Dunbar, M. [9 ]
Cerri, E. [9 ]
Enschede, S. H. [9 ]
Humerickhouse, R. A. [9 ]
Roberts, A. W. [7 ,8 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Univ Wisconsin, Madison, WI 53706 USA
[5] Univ Washington, Seattle, WA 98195 USA
[6] Univ Texas Houston, Houston, TX USA
[7] Royal Melbourne Hosp, Melbourne, Vic, Australia
[8] Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia
[9] AbbVie, N Chicago, IL USA
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S1348
引用
收藏
页码：525 / 525
页数：1
相关论文
共 50 条
  • [41] Preliminary Results of a Phase 1b Study (GP28331) Combining GDC-0199 (ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia
    Flinn, Ian
    Brunvand, Mark
    Dyer, Martin J. S.
    Hillman, Peter
    Jones, Jeffrey
    Lymp, James
    Elhamy, Mostafa
    Vosganian, Gregory
    Huang, Jane
    Kipps, Thomas J.
    BLOOD, 2014, 124 (21)
  • [42] Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma
    Barr, Paul M.
    Miller, Thomas P.
    Friedberg, Jonathan W.
    Peterson, Derick R.
    Baran, Andrea M.
    Herr, Megan
    Spier, Catherine M.
    Cui, Haiyan
    Roe, Denise J.
    Persky, Daniel O.
    Casulo, Carla
    Littleton, Jamie
    Schwartz, Mark
    Puvvada, Soham
    Landowski, Terry H.
    Rimsza, Lisa M.
    Dorr, Robert T.
    Fisher, Richard I.
    Bernstein, Steven H.
    Briehl, Margaret M.
    BLOOD, 2014, 124 (08) : 1259 - 1265
  • [43] Phase II study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin's lymphoma
    Dang, NH
    Hagemeister, FB
    Pro, B
    McLaughlin, P
    Romaguera, JE
    Jones, D
    Samuels, B
    Samaniego, F
    Younes, A
    Wang, M
    Goy, A
    Rodriguez, MA
    Walker, PL
    Arredondo, Y
    Tong, AT
    Fayad, L
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (20) : 4095 - 4102
  • [44] Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma.
    Batlevi, Connie Lee
    De Frank, Stephanie
    Stewart, Caitlin
    Hamlin, Paul A.
    Matasar, Matthew J.
    Gerecitano, John F.
    Moskowitz, Alison J.
    Hamilton, Audrey M.
    Zelenetz, Andrew David
    Drullinsky, Pamela
    Straus, David J.
    Kumar, Anita
    Moskowitz, Craig H.
    Dicostanzo, Joanna
    Callan, Devin
    Tsui, Dana
    Rademaker, Jurgen
    Schoder, Heiko
    Ni, Ai
    Younes, Anas
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
    Flinn, Ian W.
    Bartlett, Nancy L.
    Blum, Kristie A.
    Ardeshna, Kirit M.
    LaCasce, Ann S.
    Flowers, Christopher R.
    Shustov, Andrei R.
    Thress, Kenneth S.
    Mitchell, Patrick
    Zheng, Fred
    Skolnik, Jeffrey M.
    Friedberg, Jonathan W.
    EUROPEAN JOURNAL OF CANCER, 2016, 54 : 11 - 17
  • [46] Rituximab in combination with interferon-alpha in relapsed and refractory diffuse large B-cell non-Hodgkin's lymphoma
    Bertè, R
    Vallisa, D
    Civardi, G
    Moroni, CF
    Lazzaro, A
    Cavanna, L
    ACTA HAEMATOLOGICA, 2001, 106 (03) : 141 - 142
  • [47] A Phase ll Trial to Evaluate the Efficacy of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
    Flinn, Ian
    Bartlett, Nancy L.
    Blum, Kristie A.
    Ardeshna, Kirit M.
    LaCasce, Ann
    Flowers, Christopher R.
    Shustov, Andrei R.
    Thress, Kenneth
    Zheng, Fred
    Skolnik, Jeffery
    Friedberg, Jonathan W.
    BLOOD, 2014, 124 (21)
  • [48] Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
    Seymour, John Francis
    Davids, Matthew Steven
    Pagel, John M.
    Kahl, Brad S.
    Wierda, William G.
    Miller, Thomas P.
    Gerecitano, John F.
    Kipps, Thomas J.
    Anderson, Mary Ann
    Huang, David C. S.
    Darden, David E.
    Gressick, Lori A.
    Nolan, Cathy E.
    Yang, Jianning
    Busman, Todd A.
    Graham, Alison M.
    Cerri, Elisa
    Enschede, Sari H.
    Humerickhouse, Rod A.
    Roberts, Andrew Warwick
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [49] Preliminary Results of a Phase 1b Study (GO28440) Combining GDC-0199 (ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia
    Salles, Gilles Andre
    Boyd, Thomas E.
    Morschhauser, Franck
    Wendtner, Clemens-Martin
    Lymp, James
    Hilger, James
    Vosganian, Gregory
    Huang, Jane
    Stilgenbauer, Stephan
    BLOOD, 2014, 124 (21)
  • [50] ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study.
    Ma, Shuo
    Seymour, John Francis
    Lanasa, Mark C.
    Kipps, Thomas J.
    Barrientos, Jacqueline Claudia
    Davids, Matthew Steven
    Mason-Bright, Tanita
    Rudersdorf, Nikita
    Yang, Jianning
    Munasinghe, Wijith
    Zhu, Ming
    Cerri, Elisa
    Enschede, Sari H.
    Humerickhouse, Rod
    Roberts, Andrew Warwick
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345